Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in South Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 39 | 32% |
| 2020 | 1 | 43 | 35% |
| 2021 | 0 | 64 | 40% |
| 2022 | 2 | 140 | 43% |
| 2023 | 3 | 135 | 46% |
| 2024 | 3 | 206 | 48% |
| 2025 from claims | – | 206 167–242 | 49% |
| 2026 forecast | – | 228 179–287 | 50% |
| 2027 forecast | – | 252 187–334 | 50% |
| 2028 forecast | – | 279 197–385 | 51% |
| 2029 forecast | – | 308 209–441 | 51% |
| 2030 forecast | – | 340 222–504 | 52% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in South Carolina; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 25% inpatient hospital, 61% hospital outpatient, 14% surgery center. The share outside the hospital has moved −25 pts since 2024.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 20 | 1,201+17%/yr | +17%/yr | 0.5 | 59% | 2,330 in 2030+12%/yr |
| Florida | 18 | 1,158+12%/yr | +12%/yr | 0.5 | 66% | 2,840 in 2030+16%/yr |
| Oklahoma | 9 | 370+24%/yr | +24%/yr | 0.7 | 54% | 610 in 2030+8.7%/yr |
| Georgia | 7 | 300+10%/yr | +10%/yr | 0.3 | 67% | 370 in 2030+3.5%/yr |
| Tennessee | 3 | 175+24%/yr | +24%/yr | 0.2 | 16% | 320 in 2030+11%/yr |
| Virginia | 3 | 167+8.3%/yr | +8.3%/yr | 0.1 | 0% | 390 in 2030+15%/yr |
| North Carolina | 3 | 167+8.3%/yr | +8.3%/yr | 0.1 | 13% | 340 in 2030+13%/yr |
| Maryland | 2 | 164+22%/yr | +22%/yr | 0.2 | 0% | 290 in 2030+10%/yr |
| Louisiana | 1 | 124+13%/yr | +13%/yr | 0.3 | 0% | 350 in 2030+19%/yr |
| Alabama | 1 | 100+11%/yr | +11%/yr | 0.2 | 0% | 60 in 2030−8.8%/yr |
| Kentucky | 2 | 100−6.4%/yr | −6.4%/yr | 0.2 | 0% | 170 in 2030+8.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 56 | 2,163−7.6%/yr | −7.6%/yr | 3.10.9× | 7% | 2,560 in 2030+2.8%/yr |
| Lumbar fusion | 56 | 2,015−1.3%/yr | −1.3%/yr | 2.80.9× | 1% | 2,510 in 2030+3.8%/yr |
| Cervical fusion & disc arthroplasty | 31 | 1,151−3.6%/yr | −3.6%/yr | 1.61.0× | 4% | 1,220 in 2030+0.9%/yr |
| Kyphoplasty & vertebroplasty | 7 | 691−9%/yr | −9%/yr | 1.00.6× | 12% | 870 in 2030+3.9%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in South Carolina · Every state · Compare with Texas
SI-BONE leads with 43% of company spending on these surgeons in 2025, +17 pts on 2024.
In 2025, 6 companies reported engagement with South Carolina’s surgeons worth $12K in consulting, speaking, meals and travel tied to these products, about $3,950 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.